Abstract
Intracellular protozoan parasites are a great threat to animal and human health. To successfully disseminate through an organism these parasites must be able to enter and exit host cells efficiently and rapidly. The inhibition of invasion or egress of obligate intracellular parasites is regarded as a goal for drug development since these processes are essential for their survival and likely to require proteins unique to the parasites. Thus, a more comprehensive knowledge of invasion and egress proteins will aid in the development of drugs and vaccines against these intracellular pathogens. In recent years, the study of a particular parasite, Toxoplasma gondii, has yielded valuable information on how invasion and egress are achieved by some protozoan parasites. Besides being a good model system for the study of parasite biology, Toxoplasma is an important human pathogen capable of causing devastating disease in both immunocompromised individuals and developing fetuses. The lack of effective, inexpensive and tolerable drugs against Toxoplasma makes the development of new therapies an imperative. The following review describes how the identification and in depth study, using proteomics, forward genetics and pharmacology of the Toxoplasma proteins involved in entering and exiting human cells provide an important starting point in identifying targets for drug discovery.
Keywords: Toxoplasma, Invasion, Egress, Proteases, AMA1
Current Pharmaceutical Design
Title: Invasion and Egress by the Obligate Intracellular Parasite Toxoplasma gondii: Potential Targets for the Development of New Antiparasitic Drugs
Volume: 13 Issue: 6
Author(s): M. D. Lavine and G. Arrizabalaga
Affiliation:
Keywords: Toxoplasma, Invasion, Egress, Proteases, AMA1
Abstract: Intracellular protozoan parasites are a great threat to animal and human health. To successfully disseminate through an organism these parasites must be able to enter and exit host cells efficiently and rapidly. The inhibition of invasion or egress of obligate intracellular parasites is regarded as a goal for drug development since these processes are essential for their survival and likely to require proteins unique to the parasites. Thus, a more comprehensive knowledge of invasion and egress proteins will aid in the development of drugs and vaccines against these intracellular pathogens. In recent years, the study of a particular parasite, Toxoplasma gondii, has yielded valuable information on how invasion and egress are achieved by some protozoan parasites. Besides being a good model system for the study of parasite biology, Toxoplasma is an important human pathogen capable of causing devastating disease in both immunocompromised individuals and developing fetuses. The lack of effective, inexpensive and tolerable drugs against Toxoplasma makes the development of new therapies an imperative. The following review describes how the identification and in depth study, using proteomics, forward genetics and pharmacology of the Toxoplasma proteins involved in entering and exiting human cells provide an important starting point in identifying targets for drug discovery.
Export Options
About this article
Cite this article as:
Lavine D. M. and Arrizabalaga G., Invasion and Egress by the Obligate Intracellular Parasite Toxoplasma gondii: Potential Targets for the Development of New Antiparasitic Drugs, Current Pharmaceutical Design 2007; 13 (6) . https://dx.doi.org/10.2174/138161207780162854
DOI https://dx.doi.org/10.2174/138161207780162854 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of HIV-1 Neurotropism
Current HIV Research Amyloid-β Immunotherapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Potential Prophylactic and Therapeutic Vaccines for HSV Infections
Current Pharmaceutical Design Meet Our Editorial Board Member
Reviews on Recent Clinical Trials Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued) Bispidine as a Privileged Scaffold
Current Topics in Medicinal Chemistry Alkaloids from Piper: A Review of its Phytochemistry and Pharmacology
Mini-Reviews in Medicinal Chemistry Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Relation between Apolipoprotein E in Alzheimer’s Disease and SARS-CoV-2 and their Treatment Strategy: A Review
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: Antiretroviral, Anti-Inflammatory and Dopaminergic Substances in the Treatment of HIV-Infection (Guest Editor: Gabriele Arendt)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Acyclovir in the Treatment of Herpes Viruses – A Review
Current Medicinal Chemistry Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Treatment of Severe Cases of Pandemic (H1N1) 2009 Influenza: Review of Antivirals and Adjuvant Therapy
Recent Patents on Anti-Infective Drug Discovery Leptinaemia and Antiendothelial Antibodies in Accelerated Atherosclerosis – Is There a Relationship?
Vascular Disease Prevention (Discontinued) Small Non-Coding RNAs as Biomarkers
Recent Patents on Biomarkers Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy Antiviral Herbs - Present and Future
Infectious Disorders - Drug Targets Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry Catatonia: A Brief Update
Current Psychiatry Reviews